Trusted Resources: Education
Scientific literature and patient education texts
Open-Label Phase 1/2 Study of Vestronidase Alfa for Mucopolysaccharidosis VII
source: Molecular genetics and metabolism reports
year: 2021
authors: Jones S,Coker M,López AG,Sniadecki J,Mayhew J,Hensman P,Jurecka A
summary/abstract:Vestronidase alfa is an enzyme replacement therapy for mucopolysaccharidosis VII (MPS VII). In this open-label, phase 1/2 study, three subjects with MPS VII received intravenous vestronidase alfa administered every other week (QOW) for 14 weeks (2 mg/kg), followed by 24-week forced-dose titration (1, 4, and 2 mg/kg QOW; 8 weeks each), 36-week continuation (2 mg/kg), and long-term extension (4 mg/kg). Vestronidase alfa was well tolerated and led to dose-responsive, sustained reductions in urinary glycosaminoglycan excretion.
organization: Manchester University Hospitals NHS Foundation Trust, St Mary's Hospital, Manchester, UK.DOI: 10.1016/j.ymgmr.2021.100774
read more
Related Content
-
Fetal Therapies and Trials for Lysosomal Storage Diseases: A Survey of Attitudes of Parents and PatientsLysosomal storage diseases (LSDs) are in...
-
Denali Therapeutics Announces Continued Progress in DNL310 (ETV:IDS) Program for MPS II (Hunter Syndrome) Supporting...Denali Therapeutics Inc., a biopharmaceu...
-
Mucopolysaccharidoses Diagnosis in the Era of Enzyme Replacement Therapy in EgyptUndegraded glycosaminoglycans (GAGs) ind...
-
Europe Grants Orphan Drug Status to JR-441, ERT for Sanfilippo AThe European Commission has granted an o...
-
Understanding Mucopolysaccharidosis Type VII (MPS VII) or Sly SyndromeMPS VII, also called Sly syndrome, is a ...
-
Progression of Cardiovascular Manifestations in Adults and Children With Mucopolysaccharidoses With and Without Enzy...Cardiovascular involvement is among the ...
-
A Fortuitous but Characteristic Blood Smear Observation Allowing a Late Diagnosis of MPS-VIISly disease, described by William Sly in...